Attention Investors: Robbins Geller Rudman & Dowd LLP Announces Opportunity for Kyverna Therapeutics Inc. Shareholders with Significant Losses to Lead Investor Class Action Lawsuit
Robbins Geller Rudman & Dowd LLP Announces Deadline in Kyverna Therapeutics, Inc. Class Action Lawsuit SAN DIEGO, Dec. 20, 2024 (GLOBE NEWSWIRE) — Robbins Geller Rudman & Dowd LLP has announced that purchasers or acquirers of Kyverna Therapeutics, Inc. (NASDAQ: KYTX) common stock have until February 7, 2025 to seek appointment as lead plaintiff in…